Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Muneaki Sano"'
Autor:
Shoshu Mitsuyama, Yasuhiro Yanagita, Nobuaki Sato, Kansei Komaki, Tomomi Fujisawa, Keisuke Miyauchi, Tadashi Ikeda, Keisei Anan, Hiromitsu Jinno, Morihiko Kimura, Hiroyoshi Doihara, Mikihiro Kusama, Tadahiko Shien, Chizuko Kanbayashi, Muneaki Sano
Publikováno v:
Cancer Chemotherapy and Pharmacology
A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopa
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 23:54-60
Autor:
Muneaki Sano
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 23:186-192
Autor:
Keiko Oyanagi, Muneaki Sano
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 22:323-328
Autor:
Keiko Oyanagi, Muneaki Sano
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 21:259-264
Autor:
Kojiro Shimozuma, Kazuhiko Nakagami, Hiroji Iwata, Muneaki Sano, Masataka Yoshimoto, Norio Kohno, Hiroshi Sonoo, Hitoshi Tsuda, Yasuo Ohashi, Toru Watanabe, Goi Sakamoto, Tomoki Kitaya, Yutaka Tokuda, Shigemitsu Takashima
Publikováno v:
Journal of Clinical Oncology. 27:1368-1374
Purpose The primary aim of this study was to compare the effectiveness of oral uracil-tegafur (UFT) with that of classical cyclophosphamide, methotrexate, and fluorouracil (CMF) given as postoperative adjuvant treatment to women with node-negative, h
Autor:
Muneaki Sano
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 18:45-52
Autor:
Masafumi Kurosumi, Toshio Tabei, Nobuaki Sato, Naohito Yamamoto, Muneaki Sano, Morihikoa Kimura, Taro Asaga, Jiro Ando, Hirofumii Fujii, Kenichi Inoue
Publikováno v:
Breast Cancer. 13:166-171
Pre-clinical and clinical studies indicate that a combination of docetaxel and trastuzumab may effectively treat patients with human epidermal growth factor receptor-2 (HER-2) overexpressing metastatic breast cancer. We evaluated the efficacy and saf
Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer
Autor:
Takayuki Kinoshita, Masataka Yoshimoto, Tadashi Ikeda, Yoshifumi Komoike, Hideo Inaji, Reiki Nishimura, Tsunehiro Nishi, Eisei Shin, Hiroshi Sonoo, Sadako Akashi-Tanaka, Shigeru Murakami, Keiichi Mise, Hideaki Tsukuma, Futoshi Akiyama, Yuichi Iino, Shozo Ohsumi, Kimito Suemasu, Mikihiro Kusama, Tetsuya Taguchi, Muneaki Sano, Shunsuke Haga
Publikováno v:
Cancer. 106:35-41
BACKGROUND The clinical features of ipsilateral breast tumor recurrence (IBTR) after breast conserving therapy (BCT) for early stage breast cancer were analyzed from long-term follow-up of BCT in Japan. The purpose of this study was to clarify risk f
Autor:
Hiroshi Nakagomi, Muneaki Sano, Kiyoshi Shingu, Kazuma Maeno, Tomoyuki Fujita, Morihiko Kimura, Kimitoshi Kohno, Ken-ichi Ito, Minoru Fujimori, Shin-ichi Tsuchiya, Yoshihisa Hama, Hiroto Izumi
Publikováno v:
Clinical Cancer Research. 11:8837-8844
Purpose: The Y-box binding protein 1 (YB-1) regulates expression of P-glycoprotein encoded by the MDR1 gene. There have been no previous studies regarding the involvement of YB-1 in the development of resistance to paclitaxel. The present study was d